# Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis

## TL;DR

This study finds that Brolucizumab is more effective and safer than other drugs for treating a type of eye disease in older adults.

## Contribution

The study provides new evidence that Brolucizumab is more effective and safer than Aflibercept and Ranibizumab for neovascular age-related macular degeneration.

## Key findings

- Brolucizumab improved visual acuity and reduced retinal fluid more effectively than other anti-VEGF drugs.
- Brolucizumab was associated with fewer serious adverse events compared to other treatments.
- No significant difference was found in central subfield thickness or general adverse events.

## Abstract

To evaluate the efficacy and safety of Brolucizumab for neovascular age-related macular degeneration (n-AMD) through a systematic review and meta-analysis.

Cochrane, PubMed, Embase, and Web of Science databases were comprehensively searched for relevant studies. Stata and RevMan5.4 were applied for meta-analysis and risk of bias assessment. Data on the best-corrected visual acuity (BCVA), central subfield thickness (CSFT), presence of intraretinal fluid (IRF) and/or subretinal fluid (SRF), participants with ≥1 serious adverse events, and participants with ≥1 adverse events were analyzed.

Six studies were finally included. Meta-analysis showed statistical differences in BCVA [SMD = −0.65, 95% CI [−0.17 to −0.23], P < 0.05], the presence of IRF and/or SRF [RR = 0.67, 95% CI [0.56–0.79], P < 0.05], and the safety of participants with ≥1 serious adverse events [RR = 0.57, 95% CI [0.39–0.84], P < 0.05] between the experimental group and the control group. However, no statistical differences were observed in CSFT [SMD = −1.16, 95% CI [−2.79 to 0.47], P > 0.05] or the safety of participants with ≥1 adverse events [RR = 1.07, 95% CI [0.97–1.17], P > 0.05].

Compared to other anti-VEGF drugs such as Aflibercept and Ranibizumab, intravitreal injection of 6 mg Brolucizumab is more effective and safer for n-AMD, especially in the presence of IRF and/or SRF, and for participants with ≥1 serious adverse events.